Loading…
Loading…
WXXWY does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for WXXWY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for WXXWY and 80,000+ other tickers.
See exactly how WXXWY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for WXXWY and 80,000+ other tickers.
WuXi Biologics (Cayman) Inc. delivers integrated solutions covering the entire lifecycle of biological drug development, from initial discovery to full-scale manufacturing. These services are provided to clients worldwide, with a significant presence in China, North America, and Europe. Beyond its core offerings, the company engages in various specialized activities, including offering expert advice on biopharmaceutical technology, managing international sales agreements, and developing and providing advanced testing solutions. It also handles sales and marketing efforts, supports clinical…
WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY - Get Free Report) was the recipient of a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 46,353 shares, a drop of 81.8% from the July 15th total of 255,103 shares. Based on an average daily volume of 113,253
SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site has successfully completed its first GMP production campaign. The manufacturing process execution was completed with zero deviations, while critical process parameters remained stable and yields reached expected levels, demonstrating robust process performance and strong execution capabilities.
SUZHOU, China, June 18, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety Testing Center in Suzhou has successfully passed a Good Manufacturing Practice (GMP) inspection by the European Medicines Agency (EMA) with zero critical findings. This marks the fourth time the facility has successfully received EMA GMP certificate.
DUNDALK, Ireland, June 8, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its Ireland site won the "Overall Excellence in Life Sciences" award, the highest recognition at the 2026 Life Sciences Industry Awards. The company also was named the winner of the "Life Sciences Team of the Year" and won the "Outstanding Contribution Award.
SINGAPORE, June 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Product (DP) facility at its Singapore CRDMO Hub (Hub). Once operational, the facility will be the Company's key DP facility designed to meet the latest and most stringent requirements for international markets, with expected output of approximately 100 million units of pre-filled syringes and vials per year.